Denali Advisors LLC Takes $277,000 Position in Inotiv, Inc. (NASDAQ:NOTV)

Denali Advisors LLC acquired a new position in Inotiv, Inc. (NASDAQ:NOTV) in the 1st quarter, Holdings Channel reports. The institutional investor acquired 25,300 shares of the company’s stock, valued at approximately $277,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of NOTV. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Inotiv in the 4th quarter worth approximately $77,000. King Luther Capital Management Corp raised its holdings in Inotiv by 100.0% during the fourth quarter. King Luther Capital Management Corp now owns 98,600 shares of the company’s stock worth $362,000 after purchasing an additional 49,300 shares in the last quarter. Corton Capital Inc. bought a new stake in Inotiv during the third quarter worth approximately $58,000. KPP Advisory Services LLC acquired a new stake in Inotiv in the third quarter worth approximately $349,000. Finally, Algert Global LLC bought a new position in Inotiv during the 3rd quarter valued at $46,000. Institutional investors own 18.17% of the company’s stock.

Inotiv Stock Up 4.3 %

Shares of NASDAQ NOTV opened at $1.68 on Thursday. Inotiv, Inc. has a 12 month low of $1.51 and a 12 month high of $11.42. The company has a market cap of $43.63 million, a price-to-earnings ratio of -0.61 and a beta of 3.34. The business has a fifty day simple moving average of $2.46 and a 200-day simple moving average of $4.65.

Inotiv (NASDAQ:NOTV) last posted its quarterly earnings data on Wednesday, May 15th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.34). Inotiv had a negative return on equity of 11.23% and a negative net margin of 12.90%. The company had revenue of $119.04 million for the quarter, compared to analyst estimates of $136.74 million. As a group, sell-side analysts expect that Inotiv, Inc. will post -0.37 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Craig Hallum cut their price objective on Inotiv from $25.00 to $10.00 and set a “buy” rating for the company in a report on Thursday, May 16th. Jefferies Financial Group downgraded shares of Inotiv from a “buy” rating to a “hold” rating and cut their price target for the company from $11.50 to $3.75 in a report on Tuesday, May 14th. Finally, Lake Street Capital reaffirmed a “hold” rating and issued a $2.00 price objective (down previously from $10.00) on shares of Inotiv in a research note on Thursday, May 16th.

Inotiv Company Profile

Inotiv, Inc provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line.